Screens Completed




ChemoGenix is the pooled CRISPR/Cas9 chemogenomic screening facility platform of IRIC, Université de Montréal.

On May 17th 2024, Université de Montréal (UdeM) signed a non-exclusive licence agreement with ERS Genomics (ERS) granting access to the CVC CRISPR/Cas9 patent portfolio. With the acquisition of this license, UdeM has now launched its ChemoGenix platform using the CRISPR/Cas9 technology.

We specialize in establishing genome-wide genetic vulnerabilities and resistance to bioactive compounds. These genetic signatures can be leveraged to characterize the compound mode of action (MOA) and to identify novel gene functions.

Get in touch with us to learn how we could collaborate and help you in your project(s).



screened compounds


cell line


> 1,000 screens per year

Chemical genomics or chemogenomics is a powerful approach to study the response of cells to chemical perturbations. Genome-wide CRISPR-Cas9 genetic screens in human cells can systematically identify all gene knockouts that either suppress (rescue) or enhance (sensitize) compound effects on cell proliferation. This information can directly establish compound mechanism-of-action and identify all genes that function in the cellular process affected by the compound.

After assessing the growth inhibition of your favourite compound in our standard pre-B lymphocytic human cell line at the IRIC's High Throughput Screening Facility, we will grow our custom CRISPR/Cas9 genome-wide KO pool library in the presence of your compound. After outgrowth, sgRNA sequences are amplified from the cell population and sequenced at the IRIC's Genomics platform. Our custom bioinformatics pipeline then converts changes in sgRNA frequencies before and after compound treatment to statistically compute robust enrichment or depletion scores for all genes. The approach has already been used to characterize hundreds of drugs and other bioactive compounds, which serve as a baseline for interpreting your screen data. Our CRISPR screening platform has identified the targets of many uncharacterized compounds, revealing off-target effects for known drugs, and assigned functions to many previously uncharacterized genes.

Chemogenomics Pipeline

Our Services

Currently, we collaborate only with academia or other non-profit organizations.
Contact us to discuss a potential collaboration.

Chemogenomic Screen in NALM-6 Cells

You provide the compound
We screen it
Click here for more details.

Chemogenomic Screen in Any Cell Line

We can support you to perform any screen (your favourite cell line - proliferation-based, FACS-sorting. etc...). Please contact us for more details.

Gene by Genome-wide Double KO Essentiality Screen

Please contact us.

Chemogenomic screen in NALM-6 cells

Genome-wide CRISPR/Cas9 chemogenomic screen in human pre-B lymphocytic NALM-6 cell line

We will generate growth inhibition dose-response curves in NALM-6 cells with your compound of interest to optimize the dose (close to IC50) to be used in order to generate the most meaningful chemogenomic signature. If the compound does not inhibit growth, we will have the option to not screen your compound. After growing our genome-wide KO NALM-6 library in the presence of the compound(s), we will extract genomic DNA, PCR-amplify sgRNA sequences, do the NGS, align reads to our 278,754 sgRNA sequences, generate gene KO enrichment or depletion scores using our CRANKS algorithm.

Price: $2,400 CAD per compound


  • Navare AT, Mast FD, Olivier JP, Bertomeu T, Neal ML, Carpp LN, Kaushansky A, Coulombe-Huntington J, Tyers M, Aitchison JD. Viral protein engagement of GBF1 induces host cell vulnerability through synthetic lethality.
    J Cell Biol. 2022 Nov 7;221(11):e202011050. doi: 10.1083/jcb.202011050. Epub 2022 Oct 28. PubMed

  • Krosl J, Bordeleau ME, Moison C, MacRae T, Boivin I, Mayotte N, Gracias D, Baccelli I, Lavallée VP, Bisaillon R, Lehnertz B, Mendoza-Sanchez R, Ruel R, Bertomeu T, Coulombe-Huntington J, Boucher G, Noronha N, Pabst C, Tyers M, Gendron P, Lemieux S, Barabé F, Marinier A, Hébert J, Sauvageau G. Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia.
    Blood Adv. 2022 Jan 25;6(2):509-514. doi:10.1182/bloodadvances.2021006047. PubMed

  • Saraon P, Snider J, Schormann W, Rai A, Radulovich N, Sánchez-Osuna M, Coulombe-Huntington J, Huard C, Mohammed M, Lima-Fernandes E, Thériault B, Halabelian L, Chan M, Joshi D, Drecun L, Yao Z, Pathmanathan S, Wong V, Lyakisheva A, Aboualizadeh F, Niu L, Li F, Kiyota T, Subramanian R, Joseph B, Aman A, Prakesch M, Isaac M, Mamai A, Poda G, Vedadi M, Marcellus R, Uehling D, Leighl N, Sacher A, Samaržija M, Jakopović M, Arrowsmith C, Tyers M, Tsao MS, Andrews D, Al-Awar R, Stagljar I. Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells.
    J Mol Biol. 2021 Nov 19;433(23):167294. doi:10.1016/j.jmb.2021.167294. Epub 2021 Oct 16. PubMed

  • Sohail M, Shkreta L, Toutant J, Rabea S, Babeu JP, Huard C, Coulombe-Huntington J, Delannoy A, Placet M, Geha S, Gendron FP, Boudreau F, Tyers M, Grierson DS, Chabot B. A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells.
    NAR Cancer. 2021 May 25;3(2):zcab019. doi: 10.1093/narcan/zcab019. PubMed

  • Benslimane Y, Sánchez-Osuna M, Coulombe-Huntington J, Bertomeu T, Henry D, Huard C, Bonneil É, Thibault P, Tyers M, Harrington L. A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition.
    Aging Cell. 2021 Apr;20(4):e13331. doi: 10.1111/acel.13331. Epub 2021 Mar 4. PubMed

  • Chagraoui J, Girard S, Spinella JF, Simon L, Bonneil E, Mayotte N, MacRae T, Coulombe-Huntington J, Bertomeu T, Moison C, Tomellini E, Thibault P, Tyers M, Marinier A, Sauvageau G. UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex.
    Cell Stem Cell. 2021 Jan 7;28(1):48-62.e6. doi: 10.1016/j.stem.2020.12.002. PubMed

  • Benslimane Y, Bertomeu T, Coulombe-Huntington J, McQuaid M, Sánchez-Osuna M, Papadopoli D, Avizonis D, Russo MST, Huard C, Topisirovic I, Wurtele H, Tyers M, Harrington L. Genome-Wide Screens Reveal that Resveratrol Induces Replicative Stress in Human Cells.
    Mol Cell. 2020 Sep 3;79(5):846-856.e8. doi:10.1016/j.molcel.2020.07.010. Epub 2020 Aug 4. PubMed

  • Jacques S, van der Sloot AM, C Huard C, Coulombe-Huntington J, Tsao S, Tollis S, Bertomeu T, Culp EJ, Pallant D, Cook MA, Bonneil E, Thibault P, Wright GD, Tyers M. Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development.
    Genetics. 2020 Apr;214(4):1103-1120. doi: 10.1534/genetics.119.302851. Epub 2020 Feb 24. PubMed

  • Hill S, Reichermeier K, Scott DC, Samentar L, Coulombe-Huntington J, Izzi L, Tang X, Ibarra R, Bertomeu T, Moradian A, Sweredoski MJ, Caberoy N, Schulman BA, Sicheri F, Tyers M, Kleiger G. Robust cullin-RING ligase function is established by a multiplicity of poly-ubiquitylation pathways.
    Elife. 2019 Dec 23;8:e51163.doi: 10.7554/eLife.51163. PubMed

  • Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella JF, Corneau S, Mayotte N, Girard S, Frechette M, Blouin-Chagnon V, Leveillé K, Boivin I, MacRae T, Krosl J, Thiollier C, Lavallée VP, Kanshin E, Bertomeu T, Coulombe-Huntington J, St-Denis C, Bordeleau ME, Boucher G, Roux PP, Lemieux S, Tyers M, Thibault P, Hébert J, Marinier A, Sauvageau G. Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia.
    Cancer Cell. 2019 Jul 8;36(1):84-99.e8. doi:10.1016/j.ccell.2019.06.003. PubMed

  • Normandin K, Coulombe-Huntington J, St-Denis C, Bernard A, Bourouh M, Bertomeu T, Tyers M, Vincent Archambault V. Genetic enhancers of partial PLK1 inhibition reveal hypersensitivity to kinetochore perturbations.
    PLoS Genet. 2023 Aug 28;19(8):e1010903. doi: 10.1371/journal.pgen.1010903. eCollection 2023 Aug. PubMed

About Us

Brian Wilhelm
Principal Investigator, Scientific Director

Thierry Bertomeu
Head of Operations/Biology

Head of Bioinformatics

Li Zhang
Research assistant

Director IRIC Scientific Platforms Operations

Copyright © 2023 -- ChemoGenix-IRIC / U. de Montréal